Connect your AI

Prime Medicine PRME Non-Cash Lease Expense

Non-Cash Lease Expense at other companies

Beam TherapeuticsBEAM

$2.42M+1.6%

Sana BiotechnologySANA

$2.47M+10.5%

4D Molecular TherapeuticsFDMT

$786K+11.8%

Iovance Biotherapeutics, Inc.IOVA

$1.88M-34.6%

Other financials

Income statement

Revenue$838.0K-61.6%

Operating income-$50.7M+3.3%

Net income-$49.1M+5.3%

EPS (diluted)-$0.28+30.0%

Balance sheet

Cash & equivalents$77.8M-26.6%

Total debt$114.5M-5.5%

Total equity$76.7M-28.3%

Total assets$294.7M-10.2%

Cash flow

Operating cash flow-$42.7M+12.6%

CapEx$214.0K-91.2%

Free cash flow-$42.9M+16.3%

Valuation

Market cap$574.36M+111%

Enterprise value$611.08M+113%

P/S124×+6.3×

Profitability

Operating margin-4,498.1%-1,134pp

Net margin-4,342.4%-1,099pp

FCF margin-3,607.4%—

Returns & leverage

Return on equity-216.1%+1,519pp

Debt / equity1.5×+0.4×

Current ratio3.8×-1.0×

Where this comes from

Reported directly by Prime Medicine in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense.

The official record: Prime Medicine’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Prime Medicine's non-cash lease expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Prime Medicine's non-cash lease expense?: Prime Medicine (PRME) reported non-cash lease expense of $2.84M in Q1 2026.
How has Prime Medicine's non-cash lease expense changed year-over-year?: Prime Medicine's non-cash lease expense increased by 17.8% year-over-year, from $2.41M to $2.84M.
What is the long-term trend for Prime Medicine's non-cash lease expense?: Over 3 years (2022 to 2025), Prime Medicine's non-cash lease expense has grown at a -0.3% compound annual growth rate (CAGR), from $9.79M to $9.7M.
What does non-cash lease expense mean?: Non-cash portion of operating lease cost — the difference between straight-line lease expense and actual cash rent payments.